The question arising from the clinical use of the approved drugs is whether anti-IL17 treatment is efficacious in combating depression, irrespectively of the disease patients are suffering from (Ps, PsA or other spondylarthropathies) and whether the magnitude of IL-17 inhibition can predict the performance as per depression scale. The gene discussed is IL17A; the disease is depressive disorder.